HPB-092

· Hangzhou Polymed Biopharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HPB-092, covering 2025-08-22 to 2025-08-22. Get the full timeline:

Most recent: Clinical Trial Update: HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia [Phase 1]